Expert Interview
A Second Look: Exploring the Potential of Selinexor and Ruxolitinib in Myelofibrosis from Karyopharm Therapeutics' Phase 3 SENTRY Trial
Ticker(s): KPTI, INCY, BMY, GSKInstitution: University of Utah Health and Huntsman Cancer Institute
- Associate Professor of Medicine (Hematology) and Hematologic Malignancy Specialist at Huntsman Cancer Institute; Board-certified in Hematology and Medical Oncology
- Treats 100 patients with myelofibrosis per year within a major academic cancer center
- Specializes in hematologic malignancies including acute and chronic leukemias, myelofibrosis, and myelodysplastic syndromes, with a strong focus on genetic predisposition and telomere biology disorders; actively leads and participates in innovative clinical trials evaluating novel therapies for myeloid cancers, and contributes to national research efforts and peer-reviewed publications advancing treatment of bone marrow failure and leukemia
Are You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
